Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Sleep Disorders, Intrinsic

ClinicalTrials.gov lists 5,980 trials for Sleep Disorders, Intrinsic or a narrower condition beneath it. VA Office of Research and Development has the most among industry and government lead sponsors, with 90.

MeSH D020919 Nervous System Diseases C10 F03
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 169 Phase 1/2 Phase 1/2 62 Phase 2 Phase 2 313 Phase 2/3 Phase 2/3 59 Phase 3 Phase 3 331 Phase 4 Phase 4 325 Not applicable Not applicable 3,382 Observational Observational 1,332 Phase 1 Phase 1 169 Phase 1/2 Phase 1/2 62 Phase 2 Phase 2 313 Phase 2/3 Phase 2/3 59 Phase 3 Phase 3 331 Phase 4 Phase 4 325 Not applicable Not applicable 3,382 Observational Observational 1,332

Trials per phase (log scale)

2 more sections with rows

24 of the 5,980 trials are tagged with Sleep Disorders, Intrinsic itself; the rest are tagged with a narrower condition beneath it.

Get the Sleep Disorders, Intrinsic report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Sleep Disorders, Intrinsic trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 12 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 499

1990: 3 trials (Observational 3) 1993: 1 trials (Observational 1) 1994: 2 trials (Observational 2) 1995: 4 trials (Observational 3, Phase 2 1) 1996: 2 trials (Observational 1, Phase 2 1) 1997: 2 trials (Observational 1, Not applicable 1) 1998: 7 trials (Observational 3, Phase 4 1, Phase 3 2, Phase 2 1) 1999: 10 trials (Observational 6, Not applicable 1, Phase 4 1, Phase 2/3 2) 2000: 8 trials (Not applicable 3, Phase 4 2, Phase 3 1, Phase 2/3 1, Phase 2 1) 2001: 16 trials (Observational 4, Not applicable 3, Phase 4 3, Phase 3 2, Phase 2 2, Phase 1 2) 2002: 17 trials (Observational 2, Not applicable 3, Phase 4 1, Phase 3 7, Phase 2 3, Phase 1/2 1) 2003: 48 trials (Observational 8, Not applicable 14, Phase 4 3, Phase 3 13, Phase 2 8, Phase 1 2) 2004: 81 trials (Observational 5, Not applicable 19, Phase 4 10, Phase 3 30, Phase 2/3 1, Phase 2 12, Phase 1 4) 2005: 98 trials (Observational 13, Not applicable 30, Phase 4 13, Phase 3 26, Phase 2/3 1, Phase 2 11, Phase 1/2 1, Phase 1 3) 2006: 139 trials (Observational 21, Not applicable 38, Phase 4 25, Phase 3 24, Phase 2/3 2, Phase 2 20, Phase 1/2 2, Phase 1 7) 2007: 148 trials (Observational 35, Not applicable 38, Phase 4 22, Phase 3 23, Phase 2/3 4, Phase 2 17, Phase 1/2 2, Phase 1 7) 2008: 170 trials (Observational 34, Not applicable 68, Phase 4 15, Phase 3 21, Phase 2/3 7, Phase 2 16, Phase 1/2 2, Phase 1 7) 2009: 158 trials (Observational 36, Not applicable 76, Phase 4 10, Phase 3 11, Phase 2/3 4, Phase 2 11, Phase 1/2 3, Phase 1 7) 2010: 174 trials (Observational 44, Not applicable 73, Phase 4 10, Phase 3 16, Phase 2/3 4, Phase 2 10, Phase 1/2 5, Phase 1 12) 2011: 160 trials (Observational 34, Not applicable 73, Phase 4 6, Phase 3 17, Phase 2/3 3, Phase 2 13, Phase 1/2 2, Phase 1 12) 2012: 162 trials (Observational 37, Not applicable 77, Phase 4 12, Phase 3 18, Phase 2/3 2, Phase 2 9, Phase 1/2 1, Phase 1 6) 2013: 166 trials (Observational 32, Not applicable 102, Phase 4 14, Phase 3 4, Phase 2/3 3, Phase 2 5, Phase 1/2 2, Phase 1 4) 2014: 212 trials (Observational 56, Not applicable 119, Phase 4 15, Phase 3 7, Phase 2/3 3, Phase 2 5, Phase 1/2 1, Phase 1 6) 2015: 213 trials (Observational 44, Not applicable 130, Phase 4 10, Phase 3 7, Phase 2/3 2, Phase 2 13, Phase 1/2 1, Phase 1 6) 2016: 263 trials (Observational 54, Not applicable 164, Phase 4 19, Phase 3 10, Phase 2/3 1, Phase 2 8, Phase 1/2 4, Phase 1 3) 2017: 268 trials (Other 1, Observational 71, Not applicable 160, Phase 4 12, Phase 3 4, Phase 2 11, Phase 1/2 4, Phase 1 5) 2018: 264 trials (Other 1, Observational 69, Not applicable 159, Phase 4 11, Phase 3 6, Phase 2/3 3, Phase 2 8, Phase 1/2 2, Phase 1 5) 2019: 311 trials (Observational 77, Not applicable 178, Phase 4 19, Phase 3 9, Phase 2 14, Phase 1/2 3, Phase 1 11) 2020: 291 trials (Observational 71, Not applicable 184, Phase 4 6, Phase 3 3, Phase 2/3 1, Phase 2 15, Phase 1/2 1, Phase 1 10) 2021: 350 trials (Observational 89, Not applicable 221, Phase 4 12, Phase 3 4, Phase 2/3 1, Phase 2 12, Phase 1/2 3, Phase 1 8) 2022: 370 trials (Observational 77, Not applicable 243, Phase 4 14, Phase 3 8, Phase 2/3 4, Phase 2 14, Phase 1/2 3, Phase 1 7) 2023: 387 trials (Observational 82, Not applicable 245, Phase 4 17, Phase 3 9, Phase 2/3 2, Phase 2 18, Phase 1/2 7, Phase 1 7) 2024: 472 trials (Observational 94, Not applicable 316, Phase 4 14, Phase 3 10, Phase 2/3 1, Phase 2 22, Phase 1/2 4, Phase 1 11) 2025: 499 trials (Other 1, Observational 123, Not applicable 322, Phase 4 11, Phase 3 10, Phase 2/3 2, Phase 2 17, Phase 1/2 2, Phase 1 11)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 461
2025 499
2024 472
2023 387
2022 370
2021 350
2020 291
2019 311
2018 264
2017 268

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 530 trials starting in 2026 and about 510 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 574 trials still running at the 2026-10-09 snapshot; registered median of 18 months across 3,677 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Sleep Disorders, Intrinsic trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 169
Phase 1/2 62
Phase 2 313
Phase 2/3 59
Phase 3 331
Phase 4 325
Not applicable 3,382
Observational 1,332
Expanded access 4
Unknown 3

How many Sleep Disorders, Intrinsic trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 380
Recruiting 701
Enrolling by invitation 74
Active, not recruiting 154
Available 1

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Sleep Disorders, Intrinsic trials? (3)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
VA Office of Research and Development 90
ResMed 70
Fisher and Paykel Healthcare 68

Which drugs are being tested for Sleep Disorders, Intrinsic? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Ramelteon 36
Modafinil 23
DEXMEDETOMIDINE 22
Trazodone 22
Pitolisant 21

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Zolpidem MR 60
Eszopiclone 3 mg QHS 53
Low Dose Suvorexant 39
Melatonin PR 31
Control (placebo) group 26

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Sleep Disorders, Intrinsic trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Second secondary endpoint 947 1
Hospitalization for any cause 900 1
Primary end point 695 1
Firt secondary endpoint 662 1
Unplanned hospitalization for worsening heart failure 559 1

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Sleep Disorders, Intrinsic? (22)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Restless sleep disorder in a sample of children and adolescents with autism spectrum disorder: preliminary results from a case series. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2024 Yes
Sleep disorders in anti-NMDAR encephalitis. Neurology 2020 Yes
Sleep disorders in perinatal women. Best practice & research. Clinical obstetrics & gynaecology 2014 Yes
Effect of intermittent aerobic exercise on sleep quality and sleep disturbances in patients with rheumatoid arthritis - design of a randomized controlled trial. BMC musculoskeletal disorders 2014 Yes
Investigating efficacy of two brief mind-body intervention programs for managing sleep disturbance in cancer survivors: a pilot randomized controlled trial. Journal of cancer survivorship : research and practice 2013 Yes

Showing 5 of 22 publications.

Start your 14-day trial Email me all 22 publications as a PDF

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages